- Home
- GBX vs AGIO Comparison
GBX vs AGIO Comparison
Compare GBX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- AGIO
- Stock Information
- Founded
- GBX 1974
- AGIO 2007
- Country
- GBX United States
- AGIO United States
- Employees
- GBX N/A
- AGIO N/A
- Industry
- GBX Railroads
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- GBX Industrials
- AGIO Health Care
- Exchange
- GBX Nasdaq
- AGIO Nasdaq
- Market Cap
- GBX 1.8B
- AGIO 2.0B
- IPO Year
- GBX N/A
- AGIO 2013
- Fundamental
- Price
- GBX $41.80
- AGIO $25.03
- Analyst Decision
- GBX Hold
- AGIO Buy
- Analyst Count
- GBX 3
- AGIO 8
- Target Price
- GBX $64.00
- AGIO $56.57
- AVG Volume (30 Days)
- GBX 605.9K
- AGIO 675.1K
- Earning Date
- GBX 04-07-2025
- AGIO 05-01-2025
- Dividend Yield
- GBX 2.86%
- AGIO N/A
- EPS Growth
- GBX 73.06
- AGIO N/A
- EPS
- GBX 5.73
- AGIO 11.64
- Revenue
- GBX $3,611,800,000.00
- AGIO $36,498,000.00
- Revenue This Year
- GBX $2.49
- AGIO $41.19
- Revenue Next Year
- GBX $2.20
- AGIO $234.83
- P/E Ratio
- GBX $7.81
- AGIO $2.23
- Revenue Growth
- GBX N/A
- AGIO 36.07
- 52 Week Low
- GBX $41.40
- AGIO $24.34
- 52 Week High
- GBX $71.06
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- GBX 18.32
- AGIO 34.14
- Support Level
- GBX $50.20
- AGIO $24.34
- Resistance Level
- GBX $46.92
- AGIO $32.90
- Average True Range (ATR)
- GBX 1.98
- AGIO 1.55
- MACD
- GBX -0.84
- AGIO -0.39
- Stochastic Oscillator
- GBX 5.76
- AGIO 27.28
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.